Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin
Presented at the annual American Society of Reproductive Medicine meeting in San Francisco, CA, October 17, 2008.
Received 17 January 2009; received in revised form 7 July 2009; accepted 2 August 2009. published online 24 September 2009.
We studied the effect of metformin or placebo in a lifestyle modification program combined with oral contraceptives (OC) on quality-of-life parameters measured by the polycystic ovary syndrome (PCOS) questionnaire in obese adolescent women with validated PCOS. The quality-of-life indicators were measured at baseline and conclusion for five domains on the PCOS questionnaire, with equal improvement in scores in both placebo and metformin groups, suggesting that the addition of metformin does not add improvement to quality-of-life measures above those observed with lifestyle modification and OC treatment.
Department of Obstetrics & Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, New York
Reprint requests: Miranda Harris-Glocker, M.D., Department of Obstetrics & Gynecology University of Rochester School of Medicine and Dentistry, Rochester, NY, 601 Elmwood Avenue, Box 668, Rochester, NY 14642 (FAX: (585) 756-4967).
M.H.-G. has nothing to disclose. K.D. has nothing to disclose. L.K. has nothing to disclose. D.G. has nothing to disclose. K.H. has nothing to disclose.
Supported by National Institutes of Health grant K23 HD043881-01A1 (K.M.H.) and grant UL1 RR 024160 from the National Center for Research Resources to the University of Rochester, Rochester, New York.
ABSTRACT